Auto-generated from public data. Not the firm's stated position.
Flerie Invest appears to focus on early-stage life sciences companies, particularly in infectious disease, specialty pharmaceuticals, and gastrointestinal therapeutics, with recent portfolio activity suggesting a concentration in biotech and healthtech sectors at the Series A and Series B stages.
Generated 2 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.